Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approachHsiao-Tzu Chien, Peter van Meer, Helen Prior et al.|Regulatory Toxicology and Pharmacology|2022Cited by 32
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remainHelen Prior, Lucinda Weir, Laura Andrews et al.|Regulatory Toxicology and Pharmacology|2023Cited by 15
Current nonclinical approaches for immune assessments of immuno-oncology biotherapeuticsChristine Grimaldi, Diann Blanset, Frank R. Brennan et al.|Drug Discovery Today|2022Cited by 7